Human papillomavirus testing as a cytology gold standard: Comparing Surinam with the Netherlands

Modern Pathology

Volumn 18, Issue 3, 2005, Pages 349-353

  Wachtel, Mitchell S ^a   Boon, Mathilde E ^b   Korporaal, Hans ^b   Kok, Lambrecht P ^c  

^a St Joseph Regional Health Center   (United States)

^b LEIDEN CYTOLOGY AND PATHOLOGY LABORATORY   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Human papillomavirus; Odds ratio; Polymerase chain reaction; Prevalence; Squamous intraepithelial lesion

Indexed keywords

VIRUS DNA;

ARTICLE; COMPARATIVE STUDY; DNA DETERMINATION; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; NETHERLANDS; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURINAME; WART VIRUS;

CERVIX UTERI; CYTODIAGNOSIS; DNA, VIRAL; FEMALE; HUMANS; NETHERLANDS; PAPILLOMAVIRIDAE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURINAME; VAGINAL SMEARS;

EID: 15444367890     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800242     Document Type: Article

References (21)

1. Solomon D, Schiffman M, Tarone R. ALTS Study Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299.
2. Sherman M, Schiffman M, Cox JT. ALTS Study Group. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group. J Natl Cancer Inst 2002;94:102-107.
3. Zuna RE, Moore W, Dunn ST. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor. Mod Pathol 2001;14: 147-151.
4. Stoler MH. Toward objective quality assurance: the eyes don't have it. Am J Clin Pathol 2002;117:520-522.
5. Wachtel MS, Dahm PF. The ASCUS:SIL ratio and the reference laboratory pathologist. Cytopathology 2003; 14:249-256.
6. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354:20-25.
7. Wisman GB, Hollema H, de Jong S, et al. Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J Clin Oncol 1998;16: 2238-2245.
8. Krul EJ, Van De Vijver MJ, Schuuring E, et al. Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country. Int J Gynecol Cancer 1999;9: 206-211.
9. Boon ME, Suurmeijer AJH (eds). The precursor lesions. In: The Pap Smear 2nd edn. Coulomb Press Leyden: Leiden, The Netherlands, 1993, pp 105-149.
10. Reesink-Peters N, Helder MN, Wisman GB, et al. Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia. J Clin Pathol 2003;56:31-35.
11. Ngan HY, Cheung AN, Liu SS, et al. Telomerase assay and HPV 16/18 typing as an adjunct to conventional cytological cervical cancer screening. Tumour Biol 2002;23:87-92.
12. Fleiss JL. Statistical Methods for Rates and Proportions 2nd edn. John Wiley & Sons, Inc.: New York, 1981.
13. Hinchliffe SA, van Velzen D, Korporaal H, et al. Transience of cervical HPV infection in sexually active, young women with normal cervicovaginal cytology. Br J Cancer 1995;72:943-945.
14. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88: 63-73.
15. Munoz N, Bosch FX, de Sanjose S, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
16. Boon ME, van Ravenswaay Claasen HH, Kok LP. Urbanization and baseline prevalence of genital infections including Candida, Trichomonas, and human papillomavirus and of a disturbed vaginal ecology as established in the Dutch Cervical Screening Program. Am J Obstet Gynecol 2002;187:365-369.
17. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002;94:1406-1414.
18. Guidozzi F. Screening for cervical cancer. Obstet Gyenecol Surv 1996;51:247-252.
19. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
20. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-474.
21. Krul EJ, Kersemaekers AM, Zomerdijk-Nooyen YA, et al. Different profiles of allelic losses in cervical carcinoma cases in Surinam and the Netherlands. Cancer 1999;86:997-1004.